A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

Introduction: Treatment of relapsed and refractory multiple myeloma (RRMM) continues to evolve as most patients are lenalidomide (LEN) refractory at the time of first relapse with its widespread use in both induction and maintenance therapy. Pomalidomide, bortezomib and dexamethasone in RRMM has dem...

Descripción completa

Detalles Bibliográficos
Autores principales: Nadeem, Omar, Mo, Clifton C, Laubach, Jacob P., Bianchi, Giada, Redd, Robert, Barth, Peter, Bayliss, Trevor J., Sanchorawala, Vaishali, Shune, Leyla, Distaso, Alexandra, Dalton, Virginia, Sperling, Adam S, Amweg, Laura, McKenney, Mary, Colson, Kathleen, Millard, Ella L, Hou, Isabella, Savell, Alexandra, Masone, Kelly, Munshi, Nikhil C., Ghobrial, Irene M., Anderson, Kenneth, Richardson, Paul G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
653.Myeloma/Amyloidosis: Therapy, excluding Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544380/
http://dx.doi.org/10.1182/blood-2020-141549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544380/
http://dx.doi.org/10.1182/blood-2020-141549

Ejemplares similares